Close
Help





JOURNAL

Breast Cancer: Basic and Clinical Research

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women

Submit a Paper


Breast Cancer: Basic and Clinical Research 2011:5 209-226

Review

Published on 09 Oct 2011

DOI: 10.4137/BCBCR.S6234


Further metadata provided in PDF



Sign up for Email Alerts and keep in touch with Breast Cancer: Basic and Clinical Research journal news, updates, events and articles

Abstract

Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P < 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early breast cancer.



Downloads

PDF  (767.34 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Breast Cancer: Basic and Clinical Research
We are delighted about the speedy and professional process.
Dr Jan Endrikat (Saarland University Hospital, Germany)
More Testimonials

Quick Links


New article and journal news notification services